Recently, Jiangsu Federation of Industry and Commerce and Jiangsu Academy of Science and Technology for Development jointly selected and released "2020 Top 100 Innovative Private Enterprises in Jiangsu Province". Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma" or "Company") was ranked 10th on the list, another honor after its inclusion in the top ten list of "Top 100 Innovative Enterprises in Jiangsu Province" and another authoritative recognition for its R&D strength and achievements in the field of scientific and technological innovation.
Screenshot of "2020 Top 100 Innovative Private Enterprises in Jiangsu Province"
This year marks the first-time selection of the top 100 innovative private enterprises in Jiangsu, which, starting from the key elements and main links of enterprise innovation, and fully considering various indicators such as total amount, intensity and height, identified excellent private enterprises with good innovation results, outstanding social and economic benefits, and robust growth. The specific indicator system includes 4 primary indicators (innovation input, innovation output, innovation performance and innovation management), 8 secondary indicators and 15 tertiary indicators.
Hansoh Pharma always takes scientific and technological innovation as the core driver for sustainable development. Relying on the established R&D centers in Lianyungang and Shanghai as well as national R&D institutions such as national enterprise technology centers and postdoctoral research workstations, the Company focuses its R&D product pipeline on central nervous system, anti-tumor, anti-infection, diabetes and other disease fields where the clinical needs are huge. The Company now has four Class 1 innovative drugs on the market and more than 100 drugs under research. It has undertaken more than 40 national-level scientific research projects including 863 Program, "Major New Drug Innovation and Development" Science and Technology Special Project, and Torch Program; has won 2 second prizes in the National Scientific and Technological Progress Award and 1 gold medal in China Patent Award; has been granted more than 300 invention patents at home and abroad; has participated in the formulation of nearly 150 national standards; and has been ranked among the top three industrial enterprises in China's pharmaceutical R&D product line for many consecutive years.
In the future, adhering to the mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma will make persistent efforts to accelerate the pace of scientific and technological innovation, continuously introduce more innovative drugs, promote the high quality development of the Company, and help build Jiangsu into a strong, prosperous, beautiful and highly civilized province and implement the "Healthy China" initiative.
